Sinus Stent Gel Formulation and Supply

The contract involves the supply of a pre-validated, biocompatible sinus stent gel designed for medical use, requiring full compliance with current good manufacturing practices and applicable hazard labeling standards. The product must be accompanied by comprehensive batch testing results and stability data to ensure consistency, safety, and performance across all delivered lots. The supplier is expected to meet stringent regulatory requirements to support integration into clinical settings under the oversight of the Department of Defense’s Medical Supply Chain division. All manufacturing and quality control processes must align with industry best practices to guarantee reliability and traceability throughout the product lifecycle. The solicitation is issued as a subcontract under NAICS code 325412 for pharmaceutical preparation, with a response deadline of July 22, 2026, and a posting date of July 16, 2026. Performance will be carried out at a military postal address in FPO, zip code 96672-4090, indicating delivery to a U.S. military facility. The requirement does not specify a set-aside status, and no point of contact is listed, suggesting that proposals should follow standard submission protocols for DLA solicitation SPE2DS26T244V. The focus is on a ready-to-use, quality-assured product with documented evidence of biocompatibility, stability, and regulatory adherence, rather than development or customization.